SCHEMBL5542425

SCHEMBL5542425

[CH2]c1ccc2[nH]c(=O)oc2c1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 5/20 0.41
NOS2 P35228 4/20 0.41
NOS3 P29474 3/20 0.41
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.41
ADRA2A P08913 1/20 0.41
TSHR P16473 1/20 0.41
THPO P40225 1/20 0.41
BLM P54132 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KMO O15229 1/20 0.39
OGT O15294 1/20 0.37
F2 P00734 1/20 0.35
CFD P00746 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
HTR1A P08908 1/20 0.32
DRD2 P14416 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542429 0.79 NOS1 (0.46) NOS1NOS2NOS3LMNACYP1A2
SCHEMBL9370667 0.78 NOS1 (0.41) NOS1NOS2NOS3LMNACYP1A2
SCHEMBL5544040 0.78 OGT (0.37) NOS1NOS2NOS3LMNACYP1A2
SCHEMBL5541858 0.78 OGT (0.37) NOS1NOS2NOS3LMNACYP1A2
SCHEMBL5537226 0.73 OGT (0.48) NOS1NOS2NOS3LMNACYP1A2
SCHEMBL5535312 0.72 MCL1 (0.47) NOS1NOS2NOS3LMNACYP1A2
SCHEMBL4416973 0.69 PSMB8 (0.61) NOS1NOS2NOS3LMNACYP1A2
SCHEMBL11151440 0.69 KMO (0.55) NOS1NOS2NOS3LMNACYP1A2
SCHEMBL5544046 0.68 NOS1 (0.46) NOS1NOS2NOS3LMNACYP1A2
SCHEMBL10222942 0.68 KMO (0.41) NOS1NOS2NOS3LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NOS1 553/4885NOS2 610/4885NOS3 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.